Key points are not available for this paper at this time.
CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. High rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients. Transient encephalopathy developed in approximately one in three patients and severe cytokine-release syndrome developed in one in five patients. (Funded by Novartis and others; ClinicalTrials.gov number, NCT02030834 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Stephen J. Schuster
Jakub Svoboda
Elise A. Chong
New England Journal of Medicine
Novartis (Switzerland)
Building similarity graph...
Analyzing shared references across papers
Loading...
Schuster et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69dd5e464917c2595e10174c — DOI: https://doi.org/10.1056/nejmoa1708566